- Home
- TKNO vs LUNG Comparison
TKNO vs LUNG Comparison
Compare TKNO & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- LUNG
- Stock Information
- Founded
- TKNO 1996
- LUNG 1995
- Country
- TKNO United States
- LUNG United States
- Employees
- TKNO N/A
- LUNG N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- LUNG Industrial Specialties
- Sector
- TKNO Health Care
- LUNG Health Care
- Exchange
- TKNO Nasdaq
- LUNG Nasdaq
- Market Cap
- TKNO 356.4M
- LUNG 124.0M
- IPO Year
- TKNO 2021
- LUNG 2020
- Fundamental
- Price
- TKNO $4.81
- LUNG $2.87
- Analyst Decision
- TKNO Buy
- LUNG Buy
- Analyst Count
- TKNO 1
- LUNG 6
- Target Price
- TKNO $5.00
- LUNG $11.53
- AVG Volume (30 Days)
- TKNO 311.3K
- LUNG 317.8K
- Earning Date
- TKNO 08-12-2025
- LUNG 07-30-2025
- Dividend Yield
- TKNO N/A
- LUNG N/A
- EPS Growth
- TKNO N/A
- LUNG N/A
- EPS
- TKNO N/A
- LUNG N/A
- Revenue
- TKNO $38,250,000.00
- LUNG $87,473,000.00
- Revenue This Year
- TKNO $8.73
- LUNG $18.02
- Revenue Next Year
- TKNO $16.53
- LUNG $18.17
- P/E Ratio
- TKNO N/A
- LUNG N/A
- Revenue Growth
- TKNO 3.79
- LUNG 19.84
- 52 Week Low
- TKNO $1.18
- LUNG $2.50
- 52 Week High
- TKNO $10.37
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- TKNO 35.41
- LUNG 39.07
- Support Level
- TKNO $4.90
- LUNG $2.62
- Resistance Level
- TKNO $5.38
- LUNG $2.88
- Average True Range (ATR)
- TKNO 0.33
- LUNG 0.17
- MACD
- TKNO 0.01
- LUNG 0.05
- Stochastic Oscillator
- TKNO 13.41
- LUNG 39.68
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.